Form 4 for LXRX LEXICON PHARMACEUTICALS, INC.
Accepted 2022-08-09 00:00:00 ET · period of report 2022-08-05 · accession 0000899243-22-028113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-08-09 | 2022-08-05 | LXRX | DEBBANE RAYMOND | Dir, 10% | P - Purchase | $2.50 | +147.4K | 5.45M | +3% | +$368.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-05 | P | A | 147,390 | $2.50 | 5,451,204 | I See Footnotes | — | — | (F2) These securities are directly held by Invus US Partners LLC (F5) Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. (F4) Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. |